Robust methodology for the discrimination of brain tumors from in vivo magnetic resonance spectra (abstract only)

2000 ◽  
Vol 20 (1) ◽  
pp. 23
Author(s):  
Yuen Yuen Barbara Lee
Keyword(s):  
Magnetic Resonance ◽  
Brain Tumors ◽  
Magnetic Resonance Spectra

scholarly journals In vivo detection of citrate in brain tumors by1H magnetic resonance spectroscopy at 3T

2013 ◽  
Vol 72 (2) ◽  
pp. 316-323 ◽  
Author(s):  
Changho Choi ◽  
Sandeep K. Ganji ◽  
Akshay Madan ◽  
Keith M. Hulsey ◽  
Zhongxu An ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Brain Tumors ◽  
Resonance Spectroscopy ◽  
In Vivo Detection

BIOM-10. PRECLINICAL PLATFORM FOR THE IDENTIFICATION OF DEUTERIUM MAGNETIC RESONANCE SPECTROSCOPY-BASED BIOMARKERS OF BRAIN TUMOR METABOLISM

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi12-vi12
Author(s):  
Georgios Batsios ◽  
Meryssa Tran ◽  
Céline Taglang ◽  
Anne Marie Gillespie ◽  
Sabrina Ronen ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Brain Tumors ◽  
Treatment Response ◽  
Lactate Production ◽  
Cell Suspensions ◽  
Response To Therapy ◽  
Resonance Spectroscopy

Abstract Metabolic reprogramming is a fundamental hallmark of cancer, which can be exploited for non-invasive tumor imaging. Deuterium magnetic resonance spectroscopy (2H-MRS) recently emerged as a novel, translational method of interrogating flux from 2H-labeled substrates to metabolic products. However, to date, preclinical studies have been performed in vivo, an endeavor which suffers from low-throughput and potential wastage of animal life, especially when considering studies of treatment response. Developing in vitro assays for monitoring metabolism of 2H-labeled substrates will enhance throughput, lead to the rapid evaluation of new 2H-based probes and enable identification of treatment response biomarkers, thereby allowing the best 2H-based probes to be translated for further in vivo assessment. The goal of this study was to develop a preclinical cell-based platform for quantifying metabolism of 2H-labeled probes in brain tumor models. Since the Warburg effect, which is characterized by elevated glycolytic production of lactate, is a metabolic phenotype of cancer, including brain tumors, we examined metabolism of 2H-glucose or 2H-pyruvate in patient-derived glioblastoma (GBM6) and oligodendroglioma (BT88) cells and compared to normal human astrocytes (NHACONTROL). Following incubation in media containing [6,6’-2H]glucose or [U-2H]pyruvate, 2H-MR spectra obtained from live cell suspensions showed elevated 2H-lactate production in GBM6 and BT88 cells relative to NHACONTROL. Importantly, 2H-lactate production from [6,6’-2H]glucose or from [U-2H]pyruvate was reduced in GBM6 or BT88 cells subjected to irradiation and temozolomide, which is standard of care for glioma patients, pointing to the utility of this method for detecting response to therapy. Collectively, we have, for the first time, demonstrated the ability to quantify metabolism of 2H-MRS probes in live cell suspensions and validated the utility of our assay for differentiating tumor from normal cells and assessing response to therapy. Our studies will expedite the identification of novel 2H-MRS probes for imaging brain tumors and potentially other types of cancer.

Localized 31P magnetic resonance spectroscopy of large pediatric brain tumors

1990 ◽  
Vol 72 (1) ◽  
pp. 65-70 ◽  
Author(s):  
Leslie N. Sutton ◽  
Robert E. Lenkinski ◽  
Bruce H. Cohen ◽  
Roger J. Packer ◽  
Robert A. Zimmerman
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Brain Tumors ◽  
Malignant Tumors ◽  
Benign Tumors ◽  
Resonance Spectroscopy ◽  
Normal Brain ◽  
Content Type ◽  
Metabolic Fingerprint

✓ Fourteen children aged 1 week to 16 years, with a variety of large or superficial brain tumors, underwent localized in vivo 31P magnetic resonance spectroscopy of their tumor. Quantitative spectral analysis was performed by measuring the area under individual peaks using a computer algorithm. In eight patients with histologically benign tumors the spectra were considered to be qualitatively indistinguishable from normal brain. The phosphocreatine/inorganic phosphate ratio (PCr/Pi) averaged 2.0. Five patients had histologically malignant tumors; qualitatively, four of these were considered to have abnormal spectra, showing a decrease in the PCr peak. The PCr/Pi ratio for this group averaged 0.85, which was significantly lower than that seen in the benign tumor group (p < 0.05). No difference between the two groups was seen in adenosine triphosphate or phosphomonoesters. It is concluded that a specific metabolic “fingerprint” for childhood brain tumors may not exist, but that some malignant tumors show a pattern suggestive of ischemia.

Classification of In Vivo Magnetic Resonance Spectra

2005 ◽  
pp. 362-369 ◽  
Author(s):  
Björn H. Menze ◽  
Michael Wormit ◽  
Peter Bachert ◽  
Matthias Lichy ◽  
Heinz-Peter Schlemmer ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Spectra

Robust methodology for the discrimination of brain tumours from in vivo magnetic resonance spectra

2000 ◽  
Vol 147 (6) ◽  
pp. 309-314 ◽  
Author(s):  
Y.Y.B. Lee ◽  
Y. Huang ◽  
P.J.G. Lisboa ◽  
W. El-Deredy ◽  
P. Harris ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Brain Tumours ◽  
Magnetic Resonance Spectra

Proton nuclear magnetic resonance spectra of brain tumors

1986 ◽  
Vol 4 (6) ◽  
pp. 503-508 ◽  
Author(s):  
Chuzo Tanaka ◽  
Shoji Naruse ◽  
Yoshiharu Horikawa ◽  
Kimiyoshi Hirakawa ◽  
Kazuo Yoshizaki ◽  
...  
Keyword(s):  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Brain Tumors ◽  
Proton Nuclear Magnetic Resonance ◽  
Nuclear Magnetic Resonance Spectra ◽  
Magnetic Resonance Spectra ◽  
Nuclear Magnetic
Sign in / Sign up

Export Citation Format

Share Document